Antitumor effect of curcumin analog on osteosarcoma through the inhibition of p300‑mediated histone acetylation.

IF 3.8 3区 医学 Q2 ONCOLOGY
Oncology reports Pub Date : 2025-04-01 Epub Date: 2025-02-21 DOI:10.3892/or.2025.8880
Yasutoshi Tatsumi, Tatsuya Masuda, Takayoshi Watanabe, Rohmad Yudi Utomo, Ummi Maryam Zulfin, Edy Meiyanto, Toshinori Ozaki, Yusuke Suenaga, Yasuhiko Kamikubo
{"title":"Antitumor effect of curcumin analog on osteosarcoma through the inhibition of p300‑mediated histone acetylation.","authors":"Yasutoshi Tatsumi, Tatsuya Masuda, Takayoshi Watanabe, Rohmad Yudi Utomo, Ummi Maryam Zulfin, Edy Meiyanto, Toshinori Ozaki, Yusuke Suenaga, Yasuhiko Kamikubo","doi":"10.3892/or.2025.8880","DOIUrl":null,"url":null,"abstract":"<p><p>Osteosarcoma (OS) is the most common malignant bone tumor in children and adolescents. Histone acetyltransferases (HATs), such as p300, CBP and PCAF, modulate numerous biological processes, including cellular proliferation and oncogenesis, through histone acetylation. In the present study, it was investigated whether the curcumin analogs such as pentagamavunon‑1 (PGV‑1) and chemoprevention curcumin analog‑1.1 (CCA‑1.1) could target p300 and suppress OS. Computational analysis indicated that PGV‑1 and CCA‑1.1 bind to the HAT domain of p300. Accordingly, these analogs efficiently inhibited the HAT activity of p300 <i>in vitro</i> and promoted OS cell apoptosis, accompanied by downregulation of acetylated histone H3 at Lys‑27 and phosphorylated oncogenic STAT3 at Tyr‑705. Finally, it was found that PGV‑1 and CCA‑1.1 but not PGV‑1, significantly attenuates the growth of OS developed on the chicken egg chorioallantoic membrane (CAM). Collectively, the present results strongly suggest that curcumin analog‑mediated targeting of p300 might provide a clue to develop an effective treatment strategy against patients with OS.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"53 4","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/or.2025.8880","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Osteosarcoma (OS) is the most common malignant bone tumor in children and adolescents. Histone acetyltransferases (HATs), such as p300, CBP and PCAF, modulate numerous biological processes, including cellular proliferation and oncogenesis, through histone acetylation. In the present study, it was investigated whether the curcumin analogs such as pentagamavunon‑1 (PGV‑1) and chemoprevention curcumin analog‑1.1 (CCA‑1.1) could target p300 and suppress OS. Computational analysis indicated that PGV‑1 and CCA‑1.1 bind to the HAT domain of p300. Accordingly, these analogs efficiently inhibited the HAT activity of p300 in vitro and promoted OS cell apoptosis, accompanied by downregulation of acetylated histone H3 at Lys‑27 and phosphorylated oncogenic STAT3 at Tyr‑705. Finally, it was found that PGV‑1 and CCA‑1.1 but not PGV‑1, significantly attenuates the growth of OS developed on the chicken egg chorioallantoic membrane (CAM). Collectively, the present results strongly suggest that curcumin analog‑mediated targeting of p300 might provide a clue to develop an effective treatment strategy against patients with OS.

骨肉瘤(OS)是儿童和青少年中最常见的恶性骨肿瘤。组蛋白乙酰转移酶(HATs),如 p300、CBP 和 PCAF,通过组蛋白乙酰化调节许多生物过程,包括细胞增殖和肿瘤发生。本研究探讨了姜黄素类似物如五加马伏农-1(PGV-1)和化学预防姜黄素类似物-1.1(CCA-1.1)能否靶向 p300 并抑制 OS。计算分析表明,PGV-1和CCA-1.1与p300的HAT结构域结合。因此,这些类似物能在体外有效抑制 p300 的 HAT 活性,促进 OS 细胞凋亡,同时下调 Lys-27 处乙酰化组蛋白 H3 和 Tyr-705 处磷酸化的致癌 STAT3。最后,研究发现,PGV-1 和 CCA-1.1 能显著抑制在鸡卵绒毛膜(CAM)上发育的 OS 的生长,但 PGV-1 不能。总之,本研究结果有力地表明,姜黄素类似物介导的p300靶向作用可能为开发针对OS患者的有效治疗策略提供了线索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology reports
Oncology reports 医学-肿瘤学
CiteScore
8.50
自引率
2.40%
发文量
187
审稿时长
3 months
期刊介绍: Oncology Reports is a monthly, peer-reviewed journal devoted to the publication of high quality original studies and reviews concerning a broad and comprehensive view of fundamental and applied research in oncology, focusing on carcinogenesis, metastasis and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信